Literature DB >> 29388862

HLA-G Gene Polymorphism in Egyptian Patients with Non-Hodgkin Lymphoma and its Clinical Outcome.

Gehan Abd-Elfatah Tawfeek1, Suzan Alhassanin2.   

Abstract

BACKGROUND: Non-Hodgkin lymphoma (NHL) is a major cancer in Egypt and worldwide and has many risk factors including genes involved in the immune response. AIM: we investigated the HLA-G 14bp gene polymorphism as a risk factor for NHL and its clinic pathologic features. The study involved 150 patients with NHL and 100 healthy control. Full histories, clinical examination, C.T scan and laboratory investigations such as CBC, LDH, ?2microglobulin and HCV RNA by qualitative real time PCR were performed for all subjects. HLA-G 14bp ins/del gene polymorphism was determined by PCR.
RESULTS: in our study, del/del, ins/del and dominant genotypes increased the risk of NHL by 11.01, 10.55 and 10.88 fold respectively (p<0.001) but the recessive genotype did not increase the risk of NHL (p=0.112). Cases with the del allele had a greater risk of NHL than those with the ins allele (p<0.001). del/del and ins/del genotypes were significantly associated with higher LDH and ?2microglobulin levels (p<0.001), lower Hb and platelet values (p<0.001), extra nodal sites (p=0.001), poor performance status (p=0.04) and relapse (p=0.001).  Conclusions:  the results suggest that HLA-G 14bp ins/del gene polymorphism is a risk factor for NHL in our Egyptian population and is associated with poor clinical pathological features. ABBREVIATIONS: Non-Hodgkin lymphoma (NHL), Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Epstein-Barr virus (EBV), human T-cell lymphotropic/leukemia virus-1 (HTLV-1).

Entities:  

Keywords:  Clinical pathological features; HLA-G 14bp gene polymorphism; non-Hodgkin lymphoma; risk factor

Mesh:

Substances:

Year:  2018        PMID: 29388862     DOI: 10.1080/08820139.2018.1430826

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  4 in total

1.  Genetic variation in the HLA-G 3'UTR 14-bp insertion/deletion and the associated cancer risk: evidence from 25 case-control studies.

Authors:  You Jiang; Jun Lu; Yue-E Wu; Xin Zhao; Liang Li
Journal:  Biosci Rep       Date:  2019-05-10       Impact factor: 3.840

Review 2.  A Review of Cancer Genetics and Genomics Studies in Africa.

Authors:  Solomon O Rotimi; Oluwakemi A Rotimi; Bodour Salhia
Journal:  Front Oncol       Date:  2021-02-15       Impact factor: 5.738

3.  Immunogenetic Relationship of HLA-G 14 bp Insertion/Deletion Polymorphism and Toll-Like Receptor 9 with Systemic Lupus Erythematosus in Egyptian Patients: A Case-Control Study.

Authors:  Shrouk A Mohammed; Laila M Al Kady; Ghada S Boghdadi; Ghada A Dawa; Marian A Gerges; Maher A El Shafai
Journal:  Int J Gen Med       Date:  2022-01-18

Review 4.  HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers.

Authors:  Peilong Li; Nan Wang; Yi Zhang; Chuanxin Wang; Lutao Du
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.